Sökning: onr:"swepub:oai:DiVA.org:liu-45525" > Risk factors for re...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05078naa a2200553 4500 | |
001 | oai:DiVA.org:liu-45525 | |
003 | SwePub | |
008 | 091011s2005 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:uu-104221 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-455252 URI |
024 | 7 | a https://doi.org/10.1097/01.TP.0000147338.34323.122 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1042212 URI |
040 | a (SwePub)liud (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Fellström, Bengt,d 1942-u Uppsala universitet,Institutionen för medicinska vetenskaper,The Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators,Fellström, B., University Hospital, Uppsala, Sweden, Department of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden4 aut0 (Swepub:uu)bengfell |
245 | 1 0 | a Risk factors for reaching renal endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) trial |
264 | 1 | c 2005 |
338 | a print2 rdacarrier | |
520 | a Background. The aim of the study was to identity risk factors for long-term renal transplant function and development of chronic allograft nephropathy (CAN) in renal transplant recipients included in the Assessment of Lescol in Renal Transplantation (ALERT) trial. Methods. The ALERT trial was a randomized, double-blind, placebo-controlled study of the effect of fluvastatin, 40 and 80 mg/day, in renal transplant recipients who were randomized to receive fluvastatin (Lescol) (n=1,050) or placebo (n=1,052) over 5 to 6 years of follow-up. Renal endpoints including graft loss or doubling of serum creatinine or death were analyzed by univariate and multivariate regression analysis in the placebo group. Results. There were 137 graft losses (13.5%) in the placebo group, mainly caused by CAN (82%). Univariate risk factors for graft loss or doubling of serum creatinine were as follows: serum creatinine, proteinuria, hypertension, pulse pressure, time since transplantation, donor age, human leukocyte antigen-DR mismatches, treatment for rejection, low high-density lipoprotein cholesterol, and smoking. Multivariate analysis revealed independent risk factors for graft loss as follows: serum creatinine (relative risk [RR], 3.12 per 100-µM increase), proteinuria (RR, 1.64 per 1-g/24 hr increase), and pulse pressure (RR, 1.12 per 10 mm Hg), whereas age was a protective factor. With patient death in the composite endpoint, diabetes mellitus, smoking, age, and number of transplantations were also risk factors. Conclusions. Independent risk factors for graft loss or doubling of serum creatinine or patient death are mainly related to renal transplant function, proteinuria, and blood pressure, which emphasizes the importance of renoprotective treatment regimens in this population. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng |
653 | a Chronic rejection | |
653 | a Graft loss | |
653 | a Renal transplantation | |
653 | a Risk factors | |
653 | a MEDICINE | |
653 | a MEDICIN | |
653 | a Kidney diseases | |
653 | a Medicin | |
700 | 1 | a Holdaas, H.u Rikshospitalet, Oslo, Norway,the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators,Univ. Klin. Charité, Berlin, Germany4 aut |
700 | 1 | a Jardine, A.G.u University of Glasgow, Glasgow, United Kingdom,the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators4 aut |
700 | 1 | a Nyberg, G.u Sahlgrenska University Hospital, Göteborg, Sweden,the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators4 aut |
700 | 1 | a Gronhagen-Riska, C.u Grönhagen-Riska, C., University Hospital, Helsinki, Finland4 aut |
700 | 1 | a Madsen, S.u Skejby Hospital, Aarhus, Denmark4 aut |
700 | 1 | a Neumayer, H.-H.u Univ. Klin. Charité, Berlin, Germany4 aut |
700 | 1 | a Cole, E.u Toronto General Hospital, Toronto, Ont., Canada4 aut |
700 | 1 | a Maes, B.u University Hospital, Leuven, Belgium4 aut |
700 | 1 | a Ambuhl, P.u Ambühl, P., University Hospital, Zürich, Switzerland4 aut |
700 | 1 | a Olsson, Andersu Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Internmedicin,Endokrin- och magtarmmedicinska kliniken US4 aut0 (Swepub:liu)andol21 |
700 | 1 | a Staffler, B.u Novartis, Basel, Switzerland4 aut |
700 | 1 | a Pedersen, T.R.u Preventive Medicine Clinic, Ullevaal University Hospital, Oslo, Norway4 aut |
710 | 2 | a Uppsala universitetb Institutionen för medicinska vetenskaper4 org |
773 | 0 | t Transplantationg 79:2, s. 205-212q 79:2<205-212x 0041-1337x 1534-6080 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-45525 |
856 | 4 8 | u https://doi.org/10.1097/01.TP.0000147338.34323.12 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-104221 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.